

In the claims:

C Please cancel claims 1, 7-12 and 14-92 without prejudice. Please amend claim 13 and add the following new claims (all of the pending claims are set forth below for the Examiner's convenience):

Sub C' ~~(11)~~  
13. (Amended) [A substantially pure] An isolated nucleic acid molecule comprising a nucleotide sequence encoding an *H. pylori* polypeptide selected from the group consisting of [HPP1 through HPP558 (JSEQ ID NOs: 401, 403, 566, 649, 683, 764, 767, 777, 815, and 833 [384-880]).

93. The isolated nucleic acid molecule of claim 13 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 17, 143, 207, 235, 297, 305 and 335.

Sub-D1  
94. An isolated nucleic acid molecule comprising a nucleotide sequence which hybridizes under stringent conditions to a nucleotide sequence encoding an *H. pylori* polypeptide selected from the group consisting of SEQ ID NOs: 401, 403, 566, 649, 683, 764, 767, 777, 815, and 833.

C2 ~~(12)~~  
95. An isolated nucleic acid molecule comprising a nucleotide sequence which hybridizes under stringent conditions to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 17, 143, 207, 235, 297, 305 and 335.

96. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having at least 60% homology with an *H. pylori* polypeptide selected from the group consisting of SEQ ID NOs: 401, 403, 566, 649, 683, 764, 767, 777, 815, and 833.

97. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 60% homology with a nucleotide sequence selected from the group consisting of SEQ ID NOs: 17, 143, 207, 235, 297, 305 and 335.

98. The isolated nucleic acid molecule of claims 13 or 93-97 further comprising vector nucleotide sequences.
99. A host cell which contains the isolated nucleic acid molecule of claim 98.
100. The host cell of claim 99 which is a bacterial host cell.
101. A host cell which contains the isolated nucleic acid molecule of claims 13 or 93-97.
102. The host cell of claim 101 which is a bacterial host cell.
103. A vaccine composition comprising an effective amount of an *H. pylori* polypeptide encoded by the nucleic acid molecule of claims 13 or 93-97 and a pharmaceutically acceptable carrier.
104. A method of treating a subject for *H. pylori* infection comprising administering to a subject a composition of claim 103 such that treatment for *H. pylori* infection occurs.
105. The method of claim 104 wherein the treatment is a prophylactic treatment.
106. The method of claim 104 wherein the treatment is a therapeutic treatment.
107. A method of evaluating a compound for the ability to bind an *H. pylori* polypeptide comprising contacting said compound with an *H. pylori* polypeptide encoded by the nucleic acid molecule of claims 13 or 93-97 and determining if said compound binds said *H. pylori* polypeptide.
108. The method of claim 107 wherein said compound is an activator of the *H. pylori* life cycle.

(WET)  
C2  
cont  
cont